| Characteristics . | Placebo . | SHR4640, 2.5 mg . | SHR4640, 5 mg . | SHR4640, 10 mg . | Benzbromarone 50 mg . | Total . |
|---|---|---|---|---|---|---|
| (n = 38) . | (n = 40) . | (n = 40) . | (n = 40) . | (n = 39) . | (n = 197) . | |
| Age, years | ||||||
| Mean (s.d.) | 42 (11) | 44 (12) | 45 (14) | 39 (13) | 42 (12) | 42 (13) |
| Range | 26 − 65 | 18 − 67 | 24 − 69 | 18 − 68 | 21 − 66 | 18 − 69 |
| BMI, kg/m2 | ||||||
| Mean (s.d.) | 26.3 (2.80) | 26.5 (2.85) | 26.5 (2.94) | 27.3 (2.76) | 27.2 (3.07) | 26.8 (2.88) |
| Range | 20.7 − 32.0 | 21.6 − 31.9 | 20.6 − 31.8 | 22.1 − 31.9 | 18.2 − 31.8 | 18.2 − 32.0 |
| Sex, n (%) | ||||||
| Male | 38 (100.0) | 40 (100.0) | 40 (100.0) | 39 (97.5) | 39 (100.0) | 196 (99.5) |
| Female | 0 | 0 | 0 | 1 (2.5) | 0 | 1 (0.5) |
| Body weight, kg | ||||||
| Mean (s.d.) | 78.2 (11.55) | 77.4 (10.13) | 77.9 (10.92) | 81.3 (11.82) | 81.9 (12.15) | 79.3 (11.37) |
| Range | 55.0 − 111.7 | 58.5 − 104.0 | 56.0 − 99.0 | 60.0 − 109.0 | 52.1 − 110.0 | 52.1 − 111.7 |
| Drinking habit, n (%) | ||||||
| Never | 15 (39.5) | 11 (27.5) | 17 (42.5) | 15 (37.5) | 14 (35.9) | 72 (36.5) |
| ≤2 times/week | 15 (39.5) | 21 (52.5) | 14 (35.0) | 16 (40.0) | 19 (48.7) | 85 (43.1) |
| >2 times/week | 0 | 1 (2.5) | 3 (7.5) | 3 (7.5) | 0 | 7 (3.6) |
| Stopped drinking | 8 (21.1) | 7 (17.5) | 6 (15.0) | 6 (15.0) | 6 (15.4) | 33 (16.8) |
| sUA, µmol/l | ||||||
| Mean (s.d.) | 595.8 (86.52) | 598.2 (84.08) | 581.4 (79.79) | 615.4 (113.73) | 590.1 (67.11) | 598.3 (94.01) |
| Range | 482 − 844 | 492 − 750 | 491 − 840 | 492 − 969 | 481 − 783 | 491 − 969 |
| Renal function, n (%) | ||||||
| eGFR 60−˂90 ml/min | 16 (42.1) | 16 (40.0) | 16 (40.0) | 16 (40.0) | 14 (35.9) | 78 (39.6) |
| eGFR ≥90 ml/min | 22 (57.9) | 24 (60.0) | 24 (60.0) | 24 (60.0) | 25 (64.1) | 119 (60.4) |
| Gout history, n (%) | 38 (100.0) | 40 (100.0) | 36 (90.0) | 38 (95.0) | 37 (94.9) | 189 (95.9) |
| Cardiovascular comorbidity or disease, n (%) | ||||||
| Hypertension | 11 (28.9) | 12 (30.0) | 10 (25.0) | 10 (25.0) | 11 (28.2) | 54 (27.4) |
| Hyperlipidaemia | 13 (34.2) | 21 (52.5) | 17 (42.5) | 12 (30.0) | 13 (33.3) | 76 (38.6) |
| Hypercholesterolaemia | 1 (2.6) | 1 (2.5) | 0 | 1 (2.5) | 1 (2.6) | 4 (2.0) |
| Diabetes mellitus | 2 (5.3) | 1 (2.5) | 2 (5.0) | 0 | 0 | 5 (2.5) |
| Renal disease, n (%) | 6 (15.8) | 7 (17.5) | 5 (12.5) | 4 (10.0) | 6 (15.4) | 28 (14.2) |
| Characteristics . | Placebo . | SHR4640, 2.5 mg . | SHR4640, 5 mg . | SHR4640, 10 mg . | Benzbromarone 50 mg . | Total . |
|---|---|---|---|---|---|---|
| (n = 38) . | (n = 40) . | (n = 40) . | (n = 40) . | (n = 39) . | (n = 197) . | |
| Age, years | ||||||
| Mean (s.d.) | 42 (11) | 44 (12) | 45 (14) | 39 (13) | 42 (12) | 42 (13) |
| Range | 26 − 65 | 18 − 67 | 24 − 69 | 18 − 68 | 21 − 66 | 18 − 69 |
| BMI, kg/m2 | ||||||
| Mean (s.d.) | 26.3 (2.80) | 26.5 (2.85) | 26.5 (2.94) | 27.3 (2.76) | 27.2 (3.07) | 26.8 (2.88) |
| Range | 20.7 − 32.0 | 21.6 − 31.9 | 20.6 − 31.8 | 22.1 − 31.9 | 18.2 − 31.8 | 18.2 − 32.0 |
| Sex, n (%) | ||||||
| Male | 38 (100.0) | 40 (100.0) | 40 (100.0) | 39 (97.5) | 39 (100.0) | 196 (99.5) |
| Female | 0 | 0 | 0 | 1 (2.5) | 0 | 1 (0.5) |
| Body weight, kg | ||||||
| Mean (s.d.) | 78.2 (11.55) | 77.4 (10.13) | 77.9 (10.92) | 81.3 (11.82) | 81.9 (12.15) | 79.3 (11.37) |
| Range | 55.0 − 111.7 | 58.5 − 104.0 | 56.0 − 99.0 | 60.0 − 109.0 | 52.1 − 110.0 | 52.1 − 111.7 |
| Drinking habit, n (%) | ||||||
| Never | 15 (39.5) | 11 (27.5) | 17 (42.5) | 15 (37.5) | 14 (35.9) | 72 (36.5) |
| ≤2 times/week | 15 (39.5) | 21 (52.5) | 14 (35.0) | 16 (40.0) | 19 (48.7) | 85 (43.1) |
| >2 times/week | 0 | 1 (2.5) | 3 (7.5) | 3 (7.5) | 0 | 7 (3.6) |
| Stopped drinking | 8 (21.1) | 7 (17.5) | 6 (15.0) | 6 (15.0) | 6 (15.4) | 33 (16.8) |
| sUA, µmol/l | ||||||
| Mean (s.d.) | 595.8 (86.52) | 598.2 (84.08) | 581.4 (79.79) | 615.4 (113.73) | 590.1 (67.11) | 598.3 (94.01) |
| Range | 482 − 844 | 492 − 750 | 491 − 840 | 492 − 969 | 481 − 783 | 491 − 969 |
| Renal function, n (%) | ||||||
| eGFR 60−˂90 ml/min | 16 (42.1) | 16 (40.0) | 16 (40.0) | 16 (40.0) | 14 (35.9) | 78 (39.6) |
| eGFR ≥90 ml/min | 22 (57.9) | 24 (60.0) | 24 (60.0) | 24 (60.0) | 25 (64.1) | 119 (60.4) |
| Gout history, n (%) | 38 (100.0) | 40 (100.0) | 36 (90.0) | 38 (95.0) | 37 (94.9) | 189 (95.9) |
| Cardiovascular comorbidity or disease, n (%) | ||||||
| Hypertension | 11 (28.9) | 12 (30.0) | 10 (25.0) | 10 (25.0) | 11 (28.2) | 54 (27.4) |
| Hyperlipidaemia | 13 (34.2) | 21 (52.5) | 17 (42.5) | 12 (30.0) | 13 (33.3) | 76 (38.6) |
| Hypercholesterolaemia | 1 (2.6) | 1 (2.5) | 0 | 1 (2.5) | 1 (2.6) | 4 (2.0) |
| Diabetes mellitus | 2 (5.3) | 1 (2.5) | 2 (5.0) | 0 | 0 | 5 (2.5) |
| Renal disease, n (%) | 6 (15.8) | 7 (17.5) | 5 (12.5) | 4 (10.0) | 6 (15.4) | 28 (14.2) |
eGFR: estimated glomerular filtration rate; sUA: serum uric acid.
| Characteristics . | Placebo . | SHR4640, 2.5 mg . | SHR4640, 5 mg . | SHR4640, 10 mg . | Benzbromarone 50 mg . | Total . |
|---|---|---|---|---|---|---|
| (n = 38) . | (n = 40) . | (n = 40) . | (n = 40) . | (n = 39) . | (n = 197) . | |
| Age, years | ||||||
| Mean (s.d.) | 42 (11) | 44 (12) | 45 (14) | 39 (13) | 42 (12) | 42 (13) |
| Range | 26 − 65 | 18 − 67 | 24 − 69 | 18 − 68 | 21 − 66 | 18 − 69 |
| BMI, kg/m2 | ||||||
| Mean (s.d.) | 26.3 (2.80) | 26.5 (2.85) | 26.5 (2.94) | 27.3 (2.76) | 27.2 (3.07) | 26.8 (2.88) |
| Range | 20.7 − 32.0 | 21.6 − 31.9 | 20.6 − 31.8 | 22.1 − 31.9 | 18.2 − 31.8 | 18.2 − 32.0 |
| Sex, n (%) | ||||||
| Male | 38 (100.0) | 40 (100.0) | 40 (100.0) | 39 (97.5) | 39 (100.0) | 196 (99.5) |
| Female | 0 | 0 | 0 | 1 (2.5) | 0 | 1 (0.5) |
| Body weight, kg | ||||||
| Mean (s.d.) | 78.2 (11.55) | 77.4 (10.13) | 77.9 (10.92) | 81.3 (11.82) | 81.9 (12.15) | 79.3 (11.37) |
| Range | 55.0 − 111.7 | 58.5 − 104.0 | 56.0 − 99.0 | 60.0 − 109.0 | 52.1 − 110.0 | 52.1 − 111.7 |
| Drinking habit, n (%) | ||||||
| Never | 15 (39.5) | 11 (27.5) | 17 (42.5) | 15 (37.5) | 14 (35.9) | 72 (36.5) |
| ≤2 times/week | 15 (39.5) | 21 (52.5) | 14 (35.0) | 16 (40.0) | 19 (48.7) | 85 (43.1) |
| >2 times/week | 0 | 1 (2.5) | 3 (7.5) | 3 (7.5) | 0 | 7 (3.6) |
| Stopped drinking | 8 (21.1) | 7 (17.5) | 6 (15.0) | 6 (15.0) | 6 (15.4) | 33 (16.8) |
| sUA, µmol/l | ||||||
| Mean (s.d.) | 595.8 (86.52) | 598.2 (84.08) | 581.4 (79.79) | 615.4 (113.73) | 590.1 (67.11) | 598.3 (94.01) |
| Range | 482 − 844 | 492 − 750 | 491 − 840 | 492 − 969 | 481 − 783 | 491 − 969 |
| Renal function, n (%) | ||||||
| eGFR 60−˂90 ml/min | 16 (42.1) | 16 (40.0) | 16 (40.0) | 16 (40.0) | 14 (35.9) | 78 (39.6) |
| eGFR ≥90 ml/min | 22 (57.9) | 24 (60.0) | 24 (60.0) | 24 (60.0) | 25 (64.1) | 119 (60.4) |
| Gout history, n (%) | 38 (100.0) | 40 (100.0) | 36 (90.0) | 38 (95.0) | 37 (94.9) | 189 (95.9) |
| Cardiovascular comorbidity or disease, n (%) | ||||||
| Hypertension | 11 (28.9) | 12 (30.0) | 10 (25.0) | 10 (25.0) | 11 (28.2) | 54 (27.4) |
| Hyperlipidaemia | 13 (34.2) | 21 (52.5) | 17 (42.5) | 12 (30.0) | 13 (33.3) | 76 (38.6) |
| Hypercholesterolaemia | 1 (2.6) | 1 (2.5) | 0 | 1 (2.5) | 1 (2.6) | 4 (2.0) |
| Diabetes mellitus | 2 (5.3) | 1 (2.5) | 2 (5.0) | 0 | 0 | 5 (2.5) |
| Renal disease, n (%) | 6 (15.8) | 7 (17.5) | 5 (12.5) | 4 (10.0) | 6 (15.4) | 28 (14.2) |
| Characteristics . | Placebo . | SHR4640, 2.5 mg . | SHR4640, 5 mg . | SHR4640, 10 mg . | Benzbromarone 50 mg . | Total . |
|---|---|---|---|---|---|---|
| (n = 38) . | (n = 40) . | (n = 40) . | (n = 40) . | (n = 39) . | (n = 197) . | |
| Age, years | ||||||
| Mean (s.d.) | 42 (11) | 44 (12) | 45 (14) | 39 (13) | 42 (12) | 42 (13) |
| Range | 26 − 65 | 18 − 67 | 24 − 69 | 18 − 68 | 21 − 66 | 18 − 69 |
| BMI, kg/m2 | ||||||
| Mean (s.d.) | 26.3 (2.80) | 26.5 (2.85) | 26.5 (2.94) | 27.3 (2.76) | 27.2 (3.07) | 26.8 (2.88) |
| Range | 20.7 − 32.0 | 21.6 − 31.9 | 20.6 − 31.8 | 22.1 − 31.9 | 18.2 − 31.8 | 18.2 − 32.0 |
| Sex, n (%) | ||||||
| Male | 38 (100.0) | 40 (100.0) | 40 (100.0) | 39 (97.5) | 39 (100.0) | 196 (99.5) |
| Female | 0 | 0 | 0 | 1 (2.5) | 0 | 1 (0.5) |
| Body weight, kg | ||||||
| Mean (s.d.) | 78.2 (11.55) | 77.4 (10.13) | 77.9 (10.92) | 81.3 (11.82) | 81.9 (12.15) | 79.3 (11.37) |
| Range | 55.0 − 111.7 | 58.5 − 104.0 | 56.0 − 99.0 | 60.0 − 109.0 | 52.1 − 110.0 | 52.1 − 111.7 |
| Drinking habit, n (%) | ||||||
| Never | 15 (39.5) | 11 (27.5) | 17 (42.5) | 15 (37.5) | 14 (35.9) | 72 (36.5) |
| ≤2 times/week | 15 (39.5) | 21 (52.5) | 14 (35.0) | 16 (40.0) | 19 (48.7) | 85 (43.1) |
| >2 times/week | 0 | 1 (2.5) | 3 (7.5) | 3 (7.5) | 0 | 7 (3.6) |
| Stopped drinking | 8 (21.1) | 7 (17.5) | 6 (15.0) | 6 (15.0) | 6 (15.4) | 33 (16.8) |
| sUA, µmol/l | ||||||
| Mean (s.d.) | 595.8 (86.52) | 598.2 (84.08) | 581.4 (79.79) | 615.4 (113.73) | 590.1 (67.11) | 598.3 (94.01) |
| Range | 482 − 844 | 492 − 750 | 491 − 840 | 492 − 969 | 481 − 783 | 491 − 969 |
| Renal function, n (%) | ||||||
| eGFR 60−˂90 ml/min | 16 (42.1) | 16 (40.0) | 16 (40.0) | 16 (40.0) | 14 (35.9) | 78 (39.6) |
| eGFR ≥90 ml/min | 22 (57.9) | 24 (60.0) | 24 (60.0) | 24 (60.0) | 25 (64.1) | 119 (60.4) |
| Gout history, n (%) | 38 (100.0) | 40 (100.0) | 36 (90.0) | 38 (95.0) | 37 (94.9) | 189 (95.9) |
| Cardiovascular comorbidity or disease, n (%) | ||||||
| Hypertension | 11 (28.9) | 12 (30.0) | 10 (25.0) | 10 (25.0) | 11 (28.2) | 54 (27.4) |
| Hyperlipidaemia | 13 (34.2) | 21 (52.5) | 17 (42.5) | 12 (30.0) | 13 (33.3) | 76 (38.6) |
| Hypercholesterolaemia | 1 (2.6) | 1 (2.5) | 0 | 1 (2.5) | 1 (2.6) | 4 (2.0) |
| Diabetes mellitus | 2 (5.3) | 1 (2.5) | 2 (5.0) | 0 | 0 | 5 (2.5) |
| Renal disease, n (%) | 6 (15.8) | 7 (17.5) | 5 (12.5) | 4 (10.0) | 6 (15.4) | 28 (14.2) |
eGFR: estimated glomerular filtration rate; sUA: serum uric acid.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
